• Pressure on agencies to adopt response-to-resistance alternatives has intensified, widening demand for tools that can control situations without injury or pain rather than provoke confrontations.
• Wrap has built its business around a Non-Lethal Response(TM) platform that converges remote restraint, training, and evidence management, spanning the BolaWrap(R) 150, Wrap Reality(TM), Wrap Vision(TM), Wrap Tactics(TM), and counter-drone solutions.
• With the July 2026 launch of WrapShield(TM) and an exclusive U.S. and NATO license to Frenel Imaging’s TPiCore(R) thermal-polarimetric sensing, Wrap is adding an AI-enabled detection layer, beginning with counter-UAS.

A Widening Market for Response-to-Resistance Technology

High-profile use-of-force incidents have driven costly litigation, strained community trust, and increased scrutiny of how officers are equipped and trained. That environment has pushed agencies toward tools that create time, distance, and tactical advantage, particularly in encounters involving individuals in mental- or behavioral-health crises and has widened the customer base beyond traditional policing into corrections, campus safety, healthcare, and transportation security. Wrap Technologies (NASDAQ: WRAP) built its business around closing the response-to-resistance gap with technology that reduces injury to everyone involved. 

The company describes itself as a global public safety technology provider developing policing solutions for law enforcement and security personnel across the United States, Europe, the Middle East, Africa and Asia Pacific. Its flagship BolaWrap(R) 150 Remote Restraint Device, along with a growing portfolio of training and evidence-management tools, is designed to give officers options that reduce injury to everyone involved.

Independent market research points to growing investment in technologies designed to help law enforcement agencies manage critical incidents more safely and effectively. Fortune Business Insights estimates this segment will expand from approximately $1.94 billion in 2025 to about $3.25 billion by 2034, reflecting a compound annual growth rate of roughly 5.9% as agencies adopt more advanced AI-enabled, autonomous, and drone-supported capabilities. At the same time, MarketsandMarkets projects the global law enforcement software market will grow from about $20.25 billion in 2025 to nearly $33 billion by 2030.

BolaWrap(R) 150 and a Regulatory Milestone

The flagship BolaWrap(R) 150 is a patented, handheld device that discharges a Kevlar(R) tether to help officers gain control of a non-compliant individual from a distance of approximately 10 to 25 feet, pairing a multi-sensory distraction of sight and sound with remote physical restraint. It is not pain-based compliance — it does not shoot, strike, shock, or incapacitate — and is intended to help officers operate pre-escalation on the force continuum. In July 2026, the U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives (“ATF”) issued a ruling classifying the BolaWrap(R) 150 as an instrument of restraint rather than a firearm or “any other weapon” under federal law, which the company believes removes regulatory uncertainty, may simplify procurement, and may expand adoption across corrections, healthcare, transportation, education, government, and private security. The BolaWrap(R) is used by over 1,000 agencies across the U.S. and in 60+ countries and is backed by IADLEST-certified training.

A Converged Non-Lethal Response(TM) Portfolio

Beyond the device, Wrap has built an integrated portfolio. Wrap Reality(TM) provides immersive VR training; Wrap Tactics(TM) delivers a policy-aligned digital training and certification system; and Wrap Vision(TM) — an all-new body-worn camera and cloud-based evidence platform built with IONODES and a made-in-America assembly roadmap — captures and manages digital evidence. Adoption increasingly takes the form of agency-wide programs that bundle hardware with recurring, subscription-based training, software, and policy support, including WrapPlus(TM) and managed services. Wrap has also extended its non-lethal principles into counter-unmanned aircraft systems (“C-UAS”) for defense and homeland-security customers, with next-generation solutions such as the 1KC Kinetic Anti-Drone Cassette, the patent-pending MERLIN-Interdictor drone-interdiction payload, and the Wraptor MX(TM) multi-shot platform.

WrapShield(TM) and Frenel’s TPiCore(R) Detection Technology

In July 2026, Wrap launched WrapShield(TM), an autonomous defense and public safety platform intended to serve as an operating layer that connects detection, decision, and response. Its three functions are Detect (advanced multi-modal sensing with AI edge processing), Orchestrate (AI-assisted, human-supervised threat classification and decision support that interoperates with government and third-party command-and-control), and Respond (integration of Wrap’s own and third-party capabilities based on mission requirements and rules of engagement). The initial application is counter-UAS.

The platform’s detection layer is anchored by a strategic investment in Frenel Imaging Ltd., an Israeli advanced-sensing company, and an exclusive U.S. and NATO license to Frenel’s proprietary TPiCore® thermal-polarimetric imaging. Where a conventional thermal camera reads a single dimension of infrared data — intensity — TPiCore(R) is designed to capture the polarization of thermal radiation at the pixel level, supporting reconstruction of an object’s physical characteristics and material composition. Wrap believes this “polarimetric fingerprint” cannot be spoofed, jammed, or turned off and requires no radio-frequency signal to detect — addressing a blind spot in the RF-based detection much of the counter-UAS market relies on. Frenel’s Division of Focal Plane architecture delivers simultaneous polarimetric and thermal data processed in real time on deployable edge hardware across drone, ground, fixed-site, naval, and handheld configurations. Frenel is a 2024 SPIE Prism Award recipient and an NVIDIA Inception Program member, and its technology is already in operational use in Israel. Wrap sees applicability extending well beyond counter-UAS — to defense ISR, autonomous vehicles, maritime domain awareness, border security, and critical-infrastructure protection.

Leadership and Financials

Founded roughly a decade ago, Wrap is led by Founder, Chairman, and CEO Scot Cohen, whose background spans more than two decades in asset management, wealth management, and capital markets, alongside President and Chief Operating Officer Jared Novick, who joined as COO in January 2024 and was promoted to President and COO in March 2025. The company is headquartered in Miami, Florida, with manufacturing operations in Southwestern Virginia. For fiscal year 2025, Wrap reported gross revenue growth of 15% to $5.2 million, driven by strong second-half momentum, and management has set a target of 100% revenue growth for 2026.

As agencies worldwide weigh how to reduce use-of-force incidents while keeping officers and the public safe, companies offering integrated restraint, training and evidence-management solutions are certain to remain part of that conversation. With a portfolio spanning the BolaWrap remote restraint device, the Wrap Reality and Wrap Tactics training platforms, the Wrap Vision evidence-management system, and its emerging counter-UAS programs, Wrap Technologies is positioning itself at the center of that shift toward integrated, non-lethal response.

For more information, visit the company’s website at Wrap.com.

NOTE TO INVESTORS: The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

• China accounts for around 60% of global mined production of magnet rare earths, while demand for the REEs that go into electric motors, wind turbines and defense systems has doubled since 2015.
• Canamera Energy Metals reported assay results from its Turvolândia Ionic Clay Rare Earth Project in Minas Gerais, Brazil, expanding the project from four to seven drill-confirmed rare earth target areas.
• The company also announced an option agreement with Nemo Resources Inc. to acquire 100% interest in the Rare Earth Ridge rare earth and niobium project in northwestern Ontario.

Rare earth elements (“REEs”) have quietly become one of the most consequential material groups in the modern economy, powering everything from electric vehicle motors to fighter jet guidance systems. Their unique magnetic and conductive properties make them nearly impossible to substitute in high-performance applications, which is precisely why supply security has become a matter of national strategy rather than simple commodity sourcing. , Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF) is one of the junior explorers working to expand that supply outside of China, and the company recently reported new drill results confirming an expanded rare earth system at its flagship Brazilian project, alongside a separate deal to option a new rare earth and niobium project in Ontario.

The scale of the challenge these companies are addressing is significant. China accounts for around 60% of global mined production of magnet rare earths and more than 90% of global refining capacity, with its dominance even greater in downstream permanent magnet manufacturing. Demand for the magnet rare earths that go into electric motors, wind turbines and defense systems has already doubled since 2015 and is projected to grow more than 30% further by 2030.

That concentration has become a geopolitical flashpoint rather than a background statistic. New Chinese export controls introduced in 2025 required foreign companies to obtain licenses for products containing Chinese-sourced rare earth materials, a rule the IEA notes extends to energy, automotive, defense, semiconductor, aerospace and data center supply chains. S&P Global has reported that pricing premiums for rare earth magnet materials are likely to persist through 2026 and beyond as non-Chinese processing capacity remains constrained, even as demand from robotics, defense and AI infrastructure keeps climbing. 

Against that backdrop, Canamera’s two most recent announcements show a company methodically building out both its resource base and its project pipeline. Earlier this month, the company reported assay results from its Turvolândia Ionic Clay Rare Earth Project in Minas Gerais, Brazil, expanding the project from four to seven drill-confirmed rare earth target areas. The standout result came from the new Rose target, where hole TUV-AUG-070 returned eight meters grading 2,238 parts per million total rare earth oxide, including three meters at 3,776 ppm near the bottom of the hole.

That release also detailed results from the Marita target, where all three reported holes ended in mineralized material with grades increasing toward the base of each hole, a pattern consistent with the ionic adsorption clay deposit model in which rare earths concentrate in the lower weathering profile above bedrock. Company geologists noted that of the 77 holes with results received so far out of 124 drilled, 62% returned at least one sample above 750 ppm total rare earth oxide, with a peak reading of 6,431 ppm at the previously reported Cordis target. Forty-seven additional results remain pending, including 20 follow-up holes at the Linda target, suggesting the company still has a substantial data release ahead of it.

Just a few days later, Canamera announced a second and distinct piece of news: an option agreement with Nemo Resources Inc. to acquire 100% interest in the Rare Earth Ridge rare earth and niobium project in northwestern Ontario. The project covers roughly 7,320 hectares across two carbonatite intrusions, a geological setting the company describes as the world’s primary natural source of rare earth elements and niobium. Canamera can earn its interest through staged share issuances over four years and is not obligated to incur minimum exploration spending, giving it flexibility over how quickly it advances the ground.

Taken together, the two releases illustrate a company advancing on parallel tracks rather than depending on a single asset. Turvolândia is transitioning from early discovery into a broader, better-defined system with multiple named targets and a large batch of assay results still to come, while Rare Earth Ridge adds a fourth prospective rare earth and niobium project to Canamera’s Ontario portfolio at minimal upfront cost. That combination of resource expansion in Brazil and low-commitment optionality in Canada reflects a fairly disciplined approach to portfolio building in a sector where exploration risk is high and access to capital can be uneven. For a junior explorer, that kind of steady, incremental progress, confirmed by qualified persons under NI 43-101 standards and reported through public disclosure, is often a more reliable signal of direction than any single headline number.

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.

• As precision oncology becomes increasingly dependent on biomarker-driven therapies, smarter clinical trial design, and advanced drug delivery technologies, companies capable of integrating may be better positioned to address some of oncology’s most persistent development challenges.
• Onco-Innovations pairs a PNKP inhibitor, a DDR target distinct from PARP, with a nanoparticle delivery system in its lead candidate ONC010, and adds AI through its Inka Health subsidiary and the SynoGraph causal AI platform
• Onco-Innovations is advancing ONC010 through IND-enabling, manufacturing, and regulatory work, while using AI-enabled tools intended to support patient stratification, trial design, and evidence generation

Cancer drug development has three persistent problems. Tumors evolve resistance to therapies that once worked. Clinical trials fail often and cost enormously, frequently because the right patients are hard to identify. And many promising drugs never reach patients because they are too toxic or too difficult to deliver. For years, researchers attacked these problems separately. A newer approach treats them as connected, combining novel biology, advanced drug delivery, and artificial intelligence into a single development strategy. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is a company building at that intersection.

New Biology: Targeting DNA Repair Beyond PARP

Cancer treatments such as radiation and chemotherapy work by damaging tumor DNA. Cancer cells survive by repairing that damage, which is why DNA Damage Response (“DDR”) inhibitors have become one of oncology’s fastest-moving categories. PARP inhibitors opened the field, but newer targets are expanding it. Onco-Innovations focuses on Polynucleotide Kinase Phosphatase, or PNKP, an enzyme central to repairing DNA strand breaks. 

Researchers are investigating PNKP inhibition through two complementary mechanisms. It sensitizes cancer cells to radiation and DNA-damaging chemotherapies, and it may produce antitumor activity as a monotherapy through synthetic lethality, in tumors that already carry specific repair deficiencies such as PTEN or SHP-1 loss. In preclinical work, PNKP inhibition has shown activity across colorectal, lung, breast, prostate, and ovarian cancers, as well as lymphoma and leukemia. Company materials describe DDR inhibitors as more than $7 billion in global sales in 2025, with PNKP positioned as an emerging class distinct from PARP.

Better Delivery: Widening the Safety Window

New biology only helps if the drug reaches the tumor. Many DDR inhibitors have struggled with off-target toxicity or poor solubility that complicates dosing. Onco’s lead candidate, ONC010, addresses that directly. It pairs A83B4C63, a small-molecule PNKP inhibitor, with a polymer micelle carrier designed to solubilize the drug, extend its time in circulation, increase tumor accumulation, and limit exposure to healthy tissue. In this design, the nanoparticle is not packaging; it is part of the therapy. 

In animal studies, the formulation slowed tumor growth, improved survival, and showed a favorable toxicity profile while increasing sensitivity to radiation and certain chemotherapies. The same delivery platform is designed to carry other hydrophobic, hard-to-deliver drugs, which the company views as a broader pipeline opportunity.

Smarter Development: Causal AI for Patients and Trials

The third front is where a drug’s path to approval is decided. Oncology trials are among the most expensive and failure-prone in medicine, and better patient selection is one of the few levers shown to improve their odds. Onco-Innovations acquired Inka Health in 2025 and, with it, SynoGraph, a causal AI prototype platform the company says is being designed to integrate real-world data, clinical evidence, and molecular insights to model treatment outcomes, safety, adverse events, and clinical trial performance.

Because regulators and clinicians remain wary of opaque systems, the platform is intended to support more transparent, auditable reasoning than conventional black-box models. The intent is practical: identify which patients are most likely to respond, design trials around them, and generate supporting evidence. Through Inka Health, the company has announced research collaborations and initiatives involving organizations including AstraZeneca and GSK.

Where the Three Meet

Individually, each of these advances is meaningful. Their potential value lies in how they interact. A more selective DNA-repair target reaches the tumor through a delivery system built for it, while AI helps choose the patients most likely to benefit and shapes the trials that test them. That is the logic behind Onco-Innovations’ dual platform, uniting DDR-targeted therapeutics with AI-driven precision oncology, and it aims squarely at the cancers that resist conventional treatment. The approach is designed to reduce development risk and shorten timelines, though, as with any preclinical program, those benefits remain to be proven in the clinic.

Building Toward First-in-Human

Onco-Innovations are preclinical and advancing toward first-in-human studies. It is running IND-enabling work with contract partners including Dalton Pharma Services and Nucro-Technics, and has established an Australian subsidiary to support planned Phase I activity through that country’s regulatory pathway. The scientific bench behind the program includes researchers involved in foundational PNKP-inhibitor work and development of the nanoparticle delivery mechanism.

Cancer rarely yields to a single idea. The more durable progress tends to come from combining them, matching the right target to the right delivery system and the right patients. Whether Onco-Innovations converts that convergence into clinical success remains to be seen, but the strategy reflects where oncology drug development is increasingly headed.

For more information, visit https://oncoinnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF

• The combination of a structurally concentrated supply base, rising geopolitical risk from the dominant Russian supplier, and persistent demand from the automotive sector creates a clear rationale for Western nations to secure alternative sources of palladium.
• The latest news from Greenland Mines confirms that its Skaergaard project just became more valuable.
• The 2026 field season is already underway at Skaergaard, with drilling, bulk sampling for metallurgical test work, geotechnical measurements, engineering studies and environmental baseline all in progress.

Palladium is one of the most strategically important metals on earth, and the supply chain that delivers it to Western manufacturers has never been more exposed. Into that gap steps Greenland Mines (NASDAQ: GRML), which just reported a 31% increase in its indicated palladium equivalent resource at its Skaergaard project in southeast Greenland, one of the largest undeveloped palladium, gold and platinum deposits in the western world.

Most people encounter palladium without knowing it. It sits inside the catalytic converter of nearly every gasoline-powered vehicle on the road, where it converts harmful exhaust gases into less toxic emissions. Automotive applications account for roughly 80% to 85% of total global palladium demand. That makes palladium’s supply chain a direct input into the global auto industry’s ability to function.

The supply picture is what makes palladium strategically sensitive. Russia accounts for approximately 40% of global palladium supply, with the bulk of that coming from Norilsk Nickel’s Arctic operations. South Africa supplies most of the rest. That means three-quarters of the world’s palladium originates in two countries, one of which has become a deeply unreliable trading partner for Western nations.

In 2025, the U.S. International Trade Commission voted to continue investigations into Russian palladium imports after determining there was reasonable indication of material injury to the U.S. industry. The original petition, filed by Sibanye-Stillwater and the United Steelworkers Union, alleged a dumping margin of 828%. The U.S. Department of Commerce issued a final affirmative determination on April 28, 2026, effectively pricing Russian palladium out of the U.S. market.

Global palladium supply has been in deficit since 2012. Annual demand exceeded supply by roughly 5–9% of total consumption in 2023 and 2024. Those deficits have been bridged by drawing down above-ground stockpiles accumulated over decades. Stockpiles do not last forever.

The combination of a structurally concentrated supply base, rising geopolitical risk from the dominant Russian supplier, and persistent demand from the automotive sector creates a clear rationale for Western nations to secure alternative sources. Greenland is politically stable, geographically accessible and sits within allied-nation critical mineral frameworks — one of the few places on earth where a large, undeveloped palladium deposit exists.

That deposit is Skaergaard, and the latest news from Greenland Mines confirms it just became more valuable. On July 15, 2026, the company reported that independent consultant SLR Consulting (Canada) Ltd. had completed the first SEC S-K 1300-compliant Technical Report Summary for the project, incorporating an updated 2026 Mineral Resource Estimate. The results were material across every key metric. Indicated palladium equivalent contained metal increased 31% to 15.0 million ounces. Indicated PdEq grade rose 36% to 3.04 grams per tonne. Inferred contained PdEq metal grew 24% to 17.49 million ounces. Inferred PdEq grade climbed 44% to 3.07 grams per tonne.

Two factors drove the upgrade. The first was updated metal price assumptions, including gold at $3,500 per ounce, which more accurately reflect the current market environment. The second was an improved geological model. SLR’s team replaced the prior panel methodology with an industry-standard block model that better reflects the true bowl-shaped geometry of the Skaergaard deposit. The prior approach had introduced artificial dilution, pushing material below cut-off that now correctly sits above it. The result is, as the company described it, the same rock but more accurately characterized and worth more per tonne mined.

Greenland Mines president Bo Møller Stensgaard put it directly: “We have taken the 2022 mineral resource — already substantial — applied current gold and palladium prices and an improved block model methodology that better reflects the true geometry of the deposit, and the result is a resource that is more than 31% larger in Indicated PdEq ounces with a grade 36% higher. That is a material upgrade in the economic quality of what Skaergaard holds.”

The S-K 1300 conversion is more than a reporting formality. It establishes Skaergaard on a U.S. regulatory foundation and creates the platform from which the company can proceed to an Initial Assessment, the S-K 1300 equivalent of a Preliminary Economic Assessment. A key focus of that assessment will be an open-pit scenario targeting near-surface mineralization on the northern plateau, where gold, palladium and platinum occur at or close to surface. Open-pit operations typically carry lower capital and operating costs than underground mining, a factor that could meaningfully improve the project’s economics and accelerate the timeline to potential production.

The 2026 field season is already underway. Drilling, bulk sampling for metallurgical test work, geotechnical measurements, engineering studies and environmental baseline work are all in progress. Results from this campaign will feed directly into the planned initial assessment. The deposit also contains elevated levels of titanium, vanadium and gallium in the surrounding iron-oxide sequence, representing potential byproduct credits subject to further evaluation.

For more information, visit www.GreenlandMines.com.

NOTE TO INVESTORS: The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML

• Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately 470,000 annual knee cartilage repair procedures and growing demand for regenerative medicine solutions.
• Regentis is advancing GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform designed to simplify treatment, improving patient outcomes while fitting current surgical workflows and supporting durable cartilage repair.
• These developments underscore the company’s broader mission: To establish a new standard of care in cartilage repair through biomaterial-based regenerative technologies.

Regentis Biomaterials (NYSE American: RGNT) is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply manage symptoms. With cartilage defects affecting hundreds of thousands of patients each year and contributing to pain, reduced mobility, and degenerative joint disease, the company is targeting one of orthopedic medicine’s largest unmet needs.

GelrinC’s commercial potential is rooted in the combination of clinical differentiation and practical adoption. The product is designed to deliver advanced cartilage repair through a practical, approximately 10-minute, single-step procedure, without cell harvesting, laboratory expansion, patient-specific manufacturing, or a second surgery. At the same time, clinical data generated to date have shown meaningful and durable improvements in pain and function, together with evidence of high-quality cartilage repair tissue. The result is a rare value proposition in orthopedics: a regenerative treatment designed to be clinically differentiated, economically practical, scalable across surgical centers, and capable of supporting faster return to daily activity and work.

Industry Validation Supports the Regenerative Medicine Thesis

The regenerative medicine sector continues to gain regulatory validation. Recent FDA De Novo authorization of TISSIUM’s suture-less tissue repair platform highlights growing acceptance of advanced biomaterials designed to improve healing and simplify procedures. While addressing a different clinical indication, the milestone reflects broader momentum supporting biomaterial-based regenerative technologies such as Regentis’ GelrinC.

GelrinC Targets a Major Unmet Need

Regentis is pursuing this opportunity through GelrinC, its proprietary hydrogel-based implant designed to support the regeneration of damaged knee cartilage through a simple, single-step procedure. Unlike many existing treatment options that require cell harvesting, laboratory processing, and extended recovery periods, GelrinC is designed as an off-the-shelf solution that can be integrated into standard surgical workflows. 

The company’s approach seeks to reduce procedural complexity while promoting durable cartilage regeneration and improved patient outcomes.

A Differentiated Biomaterials Platform

Regentis sits at the convergence of biomaterials engineering, regenerative medicine, and orthopedic innovation. Its proprietary hydrogel implant technology is engineered to support the body’s natural regenerative processes, gradually degrading as hyaline-like cartilage tissue forms.

Clinical data have demonstrated approximately 100% greater pain improvement than microfracture procedures while also showing durable cartilage repair, reinforcing GelrinC’s potential differentiation from both conventional treatments and more complex cell-based therapies.

Significant Commercial Potential

The company’s commercial opportunity is further strengthened by its focus on knee cartilage repair, which represents the largest segment of the cartilage repair market, accounting for approximately 46% of industry revenue. Management estimates the U.S. market opportunity alone exceeds $3 billion annually, providing substantial room for expansion upon regulatory approval and commercial adoption in the United States.

Following CE Mark approval in Europe, Regentis is advancing commercialization through surgeon training, market education, and Centers of Excellence engagement while continuing its Phase III U.S. clinical program.

Multiple Catalysts Underway

With CE Mark approval already secured in Europe and a pivotal Phase III clinical trial underway in the United States, Regentis continues advancing toward a PMA submission with the FDA, providing investors with multiple potential value-driving milestones over the coming years.

Positioned at the Intersection of Innovation and Growth

As regenerative medicine gains broader clinical and regulatory acceptance, Regentis is positioned at the intersection of biomaterials innovation and orthopedic care. With encouraging clinical data, a differentiated platform, and exposure to a multibillion-dollar market opportunity, the company is advancing toward several meaningful commercial and regulatory milestones.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

• Wrap Technologies treats non-lethal response as a system rather than a single device, integrating tools, training, and policy into one Non-Lethal Response(TM) ecosystem for modern public safety.
• Its platform pairs the patented BolaWrap(R) 150 remote response-to-resistance device with Wrap Reality(TM) VR training, Wrap Vision(TM) evidence management, and Wrap Tactics(TM) digital training, reinforced by IADLEST-certified instruction and human-centered policy frameworks.
• In July 2026 the company launched WrapShield(TM), extending that integrated approach from the officer’s belt to an autonomous, AI-enabled platform designed to detect, orchestrate, and respond.

A System, not a Single Device

Law enforcement officers routinely face non-compliant individuals and people in crisis in the narrow interval where verbal commands have not worked but higher levels of force are not yet warranted. Wrap Technologies (NASDAQ: WRAP) builds technology to give officers additional options in that interval, guided by a mission the company describes as helping to save lives through safer outcomes. Rather than selling a standalone tool, Wrap integrates equipment, training, and policy into a single Non-Lethal Response(TM) system so agencies can adopt response-to-resistance capabilities as a complete program.

The company’s solutions have gained meaningful traction, with more than 1,000 law enforcement agencies across 60+ countries deploying Wrap’s technology. Demonstrations continue to expand internationally, including a recent event in Italy, where multiple police agencies have already adopted the company’s solutions.

The Tool: BolaWrap(R) 150

At the center of the platform is the BolaWrap(R) 150, a patented, handheld device that discharges a Kevlar(R) tether to help officers restrain a non-compliant individual from approximately 10 to 25 feet. Wrap describes it as the only remote response-to-resistance tool designed to preserve safe distance between subject and officer without relying on pain compliance. It does not shoot, strike, shock, or incapacitate; instead, it helps officers operate earlier, in the pre-escalation phase of the force continuum. In July 2026, the U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives (“ATF”) determined that the BolaWrap(R) 150 is an instrument of restraint rather than a firearm or “any other weapon” under federal law, which the company believes supports remote restraint as a distinct category in modern public safety.

The Training and Policy Layers

Wrap surrounds the device with training and a policy that makes consistent field use possible. Wrap Reality(TM) delivers fully immersive virtual-reality scenarios to build decision-making under stress, while Wrap Tactics(TM) provides policy-aligned digital training and certification that sustains proficiency after classroom instruction ends. Wrap Vision(TM) captures and manages digital evidence to support transparency and accountability. This ecosystem is reinforced by training partnerships with the STORM Training Group and Force Science, and by human-centered, “machine-to-man” policy work with the Law Enforcement Training and Advisory Council (“LETAC”) that keeps human judgment as the ultimate authority.

The Next Evolution: The WrapShield(TM) Platform

Wrap has described WrapShield as the next evolution of the company, connecting advanced sensing, artificial intelligence, command-and-control, and measured response into a unified operating architecture. The company frames this shift around three pillars: validation (the ATF ruling establishing remote restraint as its own category), intelligence (an exclusive U.S. and NATO license to Frenel Imaging’s thermal-polarimetric sensing, adding an AI-enabled detection layer), and integration (WrapShield itself).

WrapShield is designed to connect detection, decision, and response across complex operational environments, detecting threats earlier, classifying them with AI-assisted decision support, and integrating the response technologies a customer trusts. The company describes an architecture of layered operations — detect, identify, classify, direct, respond, and escalate only when authorized — with human decision-makers designed to remain in control. Its initial application is counter-unmanned aircraft systems, with an architecture intended to expand across critical infrastructure, border security, transportation, public venues, corrections, and defense support.

Leadership and Vision

Wrap is led by Founder, Chairman, and CEO Scot Cohen, whose background spans more than two decades in asset management, wealth management, and capital markets, alongside President and Chief Operating Officer Jared Novick. Cohen has framed the company’s direction plainly: the market does not need more disconnected devices, but a unified system that brings together sensing, AI, command-and-control, and graduated, accountable response, beginning with the belt-worn BolaWrap and extending to the WrapShield platform. The company is headquartered in Miami, Florida, with manufacturing operations in Southwestern Virginia as part of a made-in-America supply-chain initiative.

During a recent interview, Cohen explained that the company’s original vision was straightforward: create a non-lethal restraint device that officers could carry on their belts and use to safely take unarmed, non-violent individuals into custody without relying on pain compliance techniques such as pepper spray or conducted energy devices. That mission has since evolved into a broader strategy of providing law enforcement agencies with an integrated ecosystem of technologies and training designed to support safer, more effective policing.

For more information, visit the company’s website at WRAP.com.

NOTE TO INVESTORS: The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP

• Safe Pro Group recently announced that it was awarded a Small Business Innovation Research (“SBIR”) contract focused on developing a new AI dataset that will be used in airfield operations.
• Specifically, the dataset will be made using images of debris and damage that are commonly encountered on military and civilian airfields and will help address common challenges that the Department of the Air Force (“DAF”) faces.
• Developing these AI datasets could rapidly expand the applicability of Safe Pro’s computer vision technology and open up a brand-new potential market opportunity in both commercial and defense airfield operations.

Safe Pro Group (NASDAQ: SPAI), a developer of AI-powered security and defense solutions, recently announced that it was awarded a Small Business Innovation Research (“SBIR”) contract by AFWERX, which is the innovation arm of the Department of the Air Force (“DAF”) (https://ibn.fm/Z0jsM).

The contract is focused on developing a new AI dataset using images of Foreign Object Debris/Damage (“FOD”) that are often found on both U.S. Air Force (“USAF”) and civilian airfields, in order to help with the most pressing issues and challenges in the DAF.

The goal of this SBIR program is to fund emerging technologies to deliver Air Force and Space Force capabilities and expand access to disruptive innovation. 

Also, AFWERX has partnered with the Air Force Research Laboratory to streamline the SBIR process by speeding up the small business experience with faster proposal to award timelines, expanding opportunities to small businesses, and getting rid of bureaucratic overhead.

Developing AI datasets for use in U.S. Air Force airfield operations could greatly expand the applicability of Safe Pro’s computer vision technology, which is designed to rapidly detect and identify small and potentially dangerous objects on both the battlefield and in post-conflict zones.

This SBIR award also follows the recent expression of interest by the U.S. Army in this capability, as the Army invited Safe Pro to provide operational support to soldiers during an airfield exercise.

Regarding the award, the Chairman and CEO of Safe Pro, Dan Erdberg, said that “The receipt of this Air Force award represents a significant new potential market opportunity for our novel AI-powered image analysis platform, expanding it into both defense and commercial airfield operations. We look forward to working with the AFWERX team on this exciting new capability and to further expanding our ability to deliver AI-powered solutions for improved situational awareness and operational decision making.”

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that develops and delivers advanced AI-powered defense and security solutions to consumers in various markets including law enforcement, defense, homeland security, and humanitarian. The core of Safe Pro’s mission revolves around computer vision software technology that rapidly identifies and detects small objects in drone images and videos.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• The Pentagon no longer treats jamming and spoofing as a contingency but as a baseline condition of modern conflict.
• Sparc AI approaches that problem from the software side rather than through new hardware, offering its Overwatch platform that delivers precision navigation and target acquisition for drones and autonomous systems.
• The company has also been building the commercial infrastructure to bring that technology to actual defense customers.

Modern militaries-built decades of doctrine on the assumption that satellites would always know where a soldier, drone or missile stood, and that assumption is now breaking down in real time. The Air Force Research Laboratory recently awarded a $49.7 million contract specifically to mature technologies that can operate without GPS, a clear signal that the Pentagon no longer treats jamming and spoofing as a contingency but as a baseline condition of modern conflict. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) has spent years building toward this moment, developing software that lets drones and autonomous systems navigate and acquire targets without GPS, radar, lidar or any external signal at all.

The scale of the disruption behind that Air Force contract is difficult to overstate. GPS satellites broadcast extremely weak signals from roughly 20,200 kilometers up, a structural weakness that adversaries have learned to exploit at scale, and IATA’s 2024 safety report documented approximately 430,000 GPS jamming and spoofing incidents over conflict zones that year, up 62% from 2023. A single jamming event tied to Russia’s Kaliningrad exclave disrupted more than 1,600 aircraft over eastern Europe in a two-day span in March 2024, and a cheap software-defined-radio jammer costing roughly $50 can already disrupt GPS across a localized area.

Similar concerns are being reported by Military.com, which noted that autonomous military systems increasingly cannot rely on GPS at all, whether the signal is jammed, spoofed or simply unavailable underground, underwater or beneath dense foliage. ANELLO Photonics CEO Mario Paniccia told the outlet that any autonomous system being built today needs the ability to operate in a GPS-denied or GPS-spoofed environment, and that jamming and spoofing are already happening rather than looming as future risks. These reports point to a defense establishment now actively funding and fielding alternatives rather than debating whether they are needed.

What both reports make clear is that the fix cannot simply be a better GPS. The signal weakness that enables jamming is a matter of physics, not engineering, which is why the Pentagon is funding multiple parallel tracks, from quantum inertial sensors to new low-earth-orbit satellite constellations to fiber optic gyroscopes, each targeting the same underlying problem from a different angle.

SPARC AI approaches that problem from the software side rather than through new hardware. The company’s Overwatch platform was built to deliver precision navigation and target acquisition for drones and autonomous systems. It’s designed to operate in denied, degraded, intermittent and limited environments. Rather than adding new sensors, it converts the low-cost inertial sensors already built into commercial drones into precision instruments through advanced mathematical modeling.  Because the approach is software only, it can be deployed at the price point and scale that modern drone operations require, from a single platform up to fleets numbering in the thousands.

That design also addresses a second battlefield vulnerability beyond GPS dependence: detectability. SPARC AI’s technology is described as zero signature, meaning it does not rely on radar, lidar or other active emissions that can reveal a platform’s position to an adversary. This is an important distinction from many competing navigation approaches that require their own detectable sensors to function. The company has extended that same software architecture into ATLAS, a mission-planning tool launched in October 2025 that runs visibility and line-of-sight simulations entirely in software, eliminating the need for the active sensing hardware that traditional terrain mapping tools require.

SPARC AI has also been building commercial infrastructure to bring that technology to actual defense customers. In November 2025, the company signed a nonexclusive global reseller agreement with Precision Technic Defence Group, a 40-year-old defense integrator with seven offices spanning Europe, the United States and Australia. This agreement gives Sparc AI a distribution channel into established military procurement relationships across those regions. In February 2026, the company announced a separate reseller partnership to bring its platform into Ukraine, beginning with field testing in what the company describes as the world’s most demanding operational environment for GPS-denied drone warfare.

Placed against the backdrop of the Air Force’s $49.7 million alt-navigation contract and the broader shift in Pentagon assumptions, SPARC AI’s positioning appears ideally timed. The company was pursuing GPS-independent navigation and zero-signature target acquisition before this became a funded federal priority, and the recent reports on battlefield GPS failure only reinforce the scale of the market its Overwatch and ATLAS platforms are built to serve.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.

• ONC010 is being developed for biomarker-selected cancers, aligning with the growing shift toward precision medicine
• The company is currently advancing ONC010 through manufacturing, and IND-enabling development programs
• Onco-Innovations combines targeted therapeutics, nanoparticle drug delivery, and AI-native discovery to address treatment-resistant cancers

Cancer treatment is undergoing one of its most significant transformations in decades. Rather than relying on the traditional “one drug fits all” approach, oncology is increasingly embracing precision medicine. This strategy uses genomic testing and biomarker analysis to identify patients most likely to benefit from specific therapies. By matching treatments to the unique biology of a patient’s tumor, physicians can improve outcomes while reducing unnecessary exposure to therapies that may offer limited clinical benefit (ibn.fm/tNpcJ).

Drug developers are increasingly designing therapies for biomarker-defined patient populations, while regulations, clinicians, and healthcare systems continue to expand the use of genomic testing to guide treatment decisions. As precision oncology becomes the new standard of care, developers capable of creating targeted therapies for genetically defined cancers are positioned to address one of oncology’s fastest-growing markets.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is aligning its development strategy with this industry transformation through ONC010, its lead nanoparticle-encapsulated Polynucleotide kinase-phosphatase (“PNKP”) inhibitor. Designed for biomarker-selected cancers, ONC010 targets tumors that may be particularly susceptible to DNA Damage Response (“DDR”) therapies. The program combines a novel therapeutic target with nanoparticle drug delivery and an AI-native discovery platform, positioning Onco-Innovations within one of oncology’s most promising areas of innovation.

As the company advances toward First-in-Human clinical studies, it is building the scientific and manufacturing foundation supporting ONC010. Recent milestones include the initiation of polymer process development and analytical characterization activities with Nanosoft Polymers, designed to establish a robust, scalable, and reproducible manufacturing platform (ibn.fm/ztsui). According to CEOThomas O’Shaughnessy, “The initiation of this work with Nanosoft represents an important step in strengthening the manufacturing and formulation foundation of ONC010.” He noted that the collaboration is helping establish “a more scalable and reproducible pathway toward future GMP manufacturing and clinical development.”

In parallel, Onco-Innovations has initiated three-species hepatocyte and liver microsome metabolism studies through Nucro-Technics, a key component of its integrated IND-enabling development strategy (ibn.fm/0UaW4). These studies are intended to characterize how ONC010 is metabolized across human, dog, and rat systems, generating data capable of supporting pharmacokinetic modeling, dose selection, toxicology planning, and future regulatory submissions. Together with ongoing chemistry, manufacturing and controls (“CMC”) activities, initiatives are designed to reduce development risk while preparing ONC010 for clinical evaluation.

Onco-Innovations operates at the intersection of precision medicine, targeted oncology, advanced drug delivery, and artificial intelligence. Its integrated development ecosystem combines proprietary PNKP inhibitors, nanoparticle formulation technologies, specialized manufacturing expertise, and AI-driven discovery tools to speed up the development of therapies for biomarker-selected cancers.

For more information, visit https://oncoinnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF

• SS Innovations will showcase its SSi Mantra surgical robotic system at the Society of Robotic Surgery (“SRS”) 2026 Annual Meeting in Florida on July 23-26.
• The presentation will feature a live kidney telesurgery broadcast from India, demonstrating the remote capabilities of the SSi Mantra platform.
• Chairman and CEO Dr. Sudhir Srivastava to participate in multiple conference presentations covering telesurgery, robotic surgery adoption and regulatory developments.
• As of July 6, 2026, more than 12,375 procedures have been completed using the SSi Mantra system, including cardiac, pediatric and telesurgical procedures.
• Approximately 2,100 physicians have already been trained on the platform, which has been used across more than 170 different surgical procedures.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, will bring its SSi Mantra surgical robotic system to one of the largest annual gatherings of robotic surgery specialists, highlighting the company’s expanding clinical experience and growing focus on remote surgical capabilities. The company announced that the SSi Mantra will be showcased during the Society of Robotic Surgery (“SRS”) 2026 Annual Meeting, scheduled for July 23-26 in Hollywood, Florida (https://ibn.fm/FkgsY).

The robotic platform will be demonstrated throughout the conference and featured in multiple technical sessions. One of the event’s focal points will be a live robotic telesurgery in which a partial nephrectomy will be performed remotely by Dr. Amitabh Singh from SS Innovations’ headquarters in Gurugram, India, on a patient at Rajeev Gandhi Cancer Institute and Research Centre in New Delhi.

The planned procedure is intended to demonstrate the capabilities of the company’s telesurgery platform in a live educational setting before surgeons, researchers and medical technology professionals attending the conference.

Company Chairman and Chief Executive Officer Dr. Sudhir Srivastava is also scheduled to participate in several presentations and panel discussions covering cardiac telesurgery, robotic surgery adoption, regulatory considerations, global access to robotic care and developments in soft-tissue robotics.

“This influential forum provides us with a prime opportunity to highlight the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user friendliness, training capabilities, and cost efficiency,” Dr. Srivastava said. “During this year’s event, I will (…) continue to share SS Innovations’ mission of democratizing global access to advanced surgical robotic care.”

SS Innovations has continued expanding the clinical use of its SSi Mantra platform during the past year. According to the company, more than 12,375 multi-specialty procedures had been completed using the robotic system as of July 6, 2026. Those cases include 653 cardiac procedures, 178 telesurgeries, and 225 pediatric surgeries.

The company also reports that approximately 2,100 physicians have received training on the SSi Mantra platform, which has been used in more than 170 different surgical procedures across multiple specialties. Those figures reflect continued growth in clinical utilization, an important metric for companies developing surgical robotics because expanding physician adoption typically generates additional experience, procedural data and training opportunities.

The SSi Mantra is designed as a modular robotic surgery platform capable of supporting a broad range of minimally invasive procedures. Its architecture includes three to five robotic arms, an open-console surgeon workstation, three-dimensional 4K visualization, integrated imaging capabilities and a suite of more than 40 robotic surgical instruments supporting specialties that include general surgery, urology, gynecology, cardiac surgery, pediatric surgery and ear, nose and throat procedures.

Among the platform’s distinguishing features is the optional SSi MantrAsana tele-surgeon console, which enables surgeons to perform procedures remotely while maintaining functionality comparable to the standard operating console.

Remote surgery remains an emerging segment within robotic medicine. While regulatory, technical and infrastructure challenges continue to shape its adoption, proponents believe telesurgery could eventually expand access to specialized surgical expertise for patients in underserved regions.

SS Innovations has stated that the SSi Mantra is the only surgical robotic platform to have been used for cardiac telesurgery. Although telesurgery continues to evolve and currently represents a relatively small portion of overall robotic surgery activity, the company views the capability as an important component of its long-term technology strategy.

Beyond remote surgery, SS Innovations continues to position the SSi Mantra as a cost-conscious alternative within the broader robotic surgery market. The company says its objective is to make robotic-assisted procedures more affordable and accessible while supporting hospitals that may face financial barriers to adopting existing robotic systems. That strategy combines technology development with physician training, clinical validation and international expansion.

SS Innovations has steadily increased both the number of installed systems and the range of procedures supported by its platform. Earlier this year, the company announced that the SSi Mantra had surpassed 10,500 cumulative procedures, a figure that has continued to grow as adoption expands.

For more information, visit the company’s website at www.SSInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII